No Data
Morgan Stanley Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Maintains Target Price $40
Morgan Stanley analyst Michael Ulz maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and maintains the target price at $40.According to TipRanks data, the analyst has a success rate of 43.0
Leerink Partners Maintains Kyverna Therapeutics(KYTX.US) With Buy Rating, Announces Target Price $48
Leerink Partners analyst Thomas Smith maintains $Kyverna Therapeutics(KYTX.US)$ with a buy rating, and sets the target price at $48.According to TipRanks data, the analyst has a success rate of 47.3%
Kyverna (KYTX) Gets RMAT Designation for CAR T-Cell Product
SPS is a rare, progressive neurological autoimmune disorder causing debilitating muscle stiffness in the torso, arms and legs, thereby affecting the ability to walk or move.
Express News | HC Wainwright & Co. Reiterates Neutral on Kyverna Therapeutics, Maintains $8 Price Target
Kyverna (KYTX) Sees Pre-Market Surge After Regulatory Milestone
Shares of Kyverna Therapeutics, Inc. (NASDAQ: KYTX) are experiencing notable momentum on the US stock charts today, following a pivotal regulatory approval. As of the latest pre-market check, KYTX stock has risen 8.78% to $10.78. RMAT Designation and Its Implications Kyverna Therapeutics (KYTX) reported that its KYV-101 has received Regenerative Medicine Advanced Therapy (RMAT) classification ...
Bank Of America, Morgan Stanley And Other 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows:Wall Street expects Bank of America Corporation (NYSE:BAC) to